Semax vs Selank: The Russian Nootropic Research Peptides, Explained

The short version: Semax and Selank are two short peptides developed within the Russian neuropeptide research tradition. They are often grouped together in the nootropic / neuropeptide research space, but in the literature they trace back to different parent molecules and are studied along different lines.

Where they come from

Both peptides emerged from Russian academic research in the late twentieth century, which is why they are so often mentioned in the same breath. Each was engineered by taking a fragment of a naturally occurring molecule and modifying it so that researchers could study a more stable, longer-lived version in the laboratory.

Semax is derived from a fragment of adrenocorticotropic hormone (ACTH), specifically a short ACTH(4–10) sequence that has been altered to resist rapid breakdown. Selank is a synthetic analogue of tuftsin, a small peptide that the immune system produces naturally. So although they are cousins by nationality and era, their family trees start in two different places.

What “nootropic peptide” actually means here

In research writing, “nootropic” is shorthand for a compound that scientists investigate for its relationship to learning, memory, attention, or stress-response pathways in study models. It is a category of research interest, not a promise.

A useful analogy: think of the brain’s signalling chemistry as a busy switchboard. Researchers use short peptides like these as small, specific probes to ask narrow questions about how certain lines on that switchboard behave. The point of the work is the question, not an outcome.

How Semax is studied in the literature

Because Semax sits in the melanocortin / ACTH-fragment family, much of the published research investigates it in the context of neurotrophic signalling — the molecular machinery associated with the maintenance and plasticity of nerve cells in study models. A recurring theme in the literature is its relationship to brain-derived neurotrophic factor (BDNF) pathways.

Researchers have also examined Semax in models relevant to learning- and attention-related pathways, and in models of neural stress. As always, these are investigations conducted in laboratory and animal models, and the published interest does not translate into any claim about people.

How Selank is studied in the literature

Selank, as a tuftsin analogue, is more often framed around the intersection of the nervous and immune systems. The research literature frequently investigates it in relation to pathways associated with stress-response and anxiety-related signalling in animal models, and explores its interaction with GABAergic and serotonergic signalling.

Its tuftsin lineage also means a portion of the research touches on immune-modulating pathways — a line of inquiry that distinguishes it from the more strictly neurotrophic emphasis seen in much of the Semax literature.

Alike, but not interchangeable

It is easy to file the two peptides under one heading, but the research framing pulls them apart. The table below summarises the differences as they appear in the literature.

Both are short peptides supplied as lyophilised (freeze-dried) powder, the standard format for handling and storage in a laboratory setting. Both belong to what JP groups as its “mind” research range, and both are studied within the broader Russian neuropeptide research lineage that links them historically.

If you remember one thing: Semax and Selank are siblings by era and origin, but in the research literature they branch from different parent molecules and are investigated along different pathways.

Where the evidence stops

• Most of what we found is rat work. The Semax BDNF paper and the Selank GABA gene paper below were both done in rats.
• The human data is small. The Selank study we found had 62 patients, compared it with another anti-anxiety drug (medazepam) rather than a placebo, and was published in Russian.
• No registered trials. We couldn’t find a Semax or Selank trial on ClinicalTrials.gov.

A note on framing

Everything above describes how these compounds appear in published research and how investigators study them in models. None of it describes use, dosing, or outcomes in people or animals, and none of it should be read as guidance of that kind. These are research-grade materials intended for laboratory study only.

Where JP fits

JP Research supplies both as research-grade material: Semax 10mg and Selank 5mg, with DSIP 10mg sitting alongside them in the same “mind” range. The 10mg Selank is sold out. Browse the catalogue to compare the rest of the range.

Where we hold an independent lab report for a product, it’s on our lab reports wall and the product page says so. Where we don’t, the product page says “No report held”.

Sources

• Dolotov et al.: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (Brain Res, 2006)
• Vyunova et al.: Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity (Protein Pept Lett, 2018)
• Volkova et al.: Selank administration affects the expression of some genes involved in GABAergic neurotransmission (Front Pharmacol, 2016)
• Zozulia et al.: Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Zh Nevrol Psikhiatr Im S S Korsakova, 2008; in Russian)

Plain-English guides on Peptide Carl: Semax and Selank. Carl is the free education site we run.